Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
seems like a lot of back-and-forth about nomenclature. i would imagine we can we all agree that an increase in sensitivity allows for (at least) a potential increase in accuracy. while sensitivity is merely a measure of how much raw data can be gathered based on the same conditions, accuracy is a measure of how correctly computations based on that data are. assuming LEX's algorithms are true, a 500% increase in raw data would likely have a profound impact on accuracy.
yup, by almost any metric, this particular "stinky pinky" is different.
i.e., we're broke and kicking the can down the road
thanks for this, well thought out
that Insider Financial article was how I initially learned of LEX
he said he likes you . . . but only as a friend
they also assume present conditions continue in perpetuity. one positive press release and their "metrics" fall apart.
not enough liquidity at that SP for any of us to jump in. it was just a false flag by an MM to induce panic.
amen Smithy
we went below .05 yesterday
thank you
yeah, working and haven't bothered to check the actual trade. i'm guessing some turd traded 100 shares.
TDAmeritrade showing 0.0482 as day low??
I admire your confidence. But you know how opinions work.
there's just no near term catalyst to keep the SP aloft. this is what OTC securities do. i would not at all be surprised to see it drop below 10 cents. the weak hands will fold and others will scoop up more shares. i'm with the latter group. i'd rather be a "bag holder" with this particular company.
any thoughts on the insiders allowing the SP to hit the skids so they can scoop up shares prior to positive PR?
yes, but he didn't use CAPITAL LETTERS ;)
this board went through a serious transition some months back. it used to be a group of pumper cheerleaders that ceaselessly sang the praises of LXGTF with utterly no substance to back it up. each of those dolts would post multiple messages a day and it was a real waste of time sifting through the garbage to get to anything of value. glad that's over.
what's the bid-2-ask ratio? - - i'm still having issues accessing that times & sales data. TOS looks like they had gamers design a trading platform . . . ridiculous. i tried on the old school TDA site and still could not find that.
i understand that. i've never held a long position without a sell order in place. i re-posted the original question with the "NOT" capitalized as I believe that is where the disconnect was. i had to re-read it myself as i misunderstood it at first too.
"i have a stupid question -- for all you veterans of the stock mark--
these mm ...if we do NOT have our stock in a sell position(locked up) can the mm go in and use for short selling???"
are you using thinkorswim? why can't i find a link to that tool on TOS?
hey, i want to thank you for your input. i don't have the time to dig into the materials like some and am thankful for folks like you that do. i usually try to avoid value investing and instead look for swing/momentum plays. this is one of the very few value plays i've made over the years.
i'm thinking we will retest the lows. there's just too much time before significant events/catalysts for that not to happen. maybe sub-.14. but again, i'm a believer and to me that just means buying more.
that's my cost basis too . . . bought all the way down to .151
i implied nothing, just asked you a simple question. you self-destructed at that point. enjoy your psychosis.
you sure you're not supposed to multiply that number by 100 ?
well here's to hoping you are right [CHEERS]. i traded out of GMO today and put those funds into LXGTF at 32 cents. only time will tell of course.
i completely agree on the "cheerleaders" comment. this place is a major rah-rah echo chamber. nonetheless, that chatter doesn't take away from the fact that this is by all appearances a viable product and merely needs testing to confirm. today was a major buying opp and if that didn't occur to you then this is not your game.
honesty appreciated
this echo chamber is non-stop
it's not my desire to do anything for you
"Lexington Biosciences ("LXGTF") has increased by more than 90% since early October of 2017. Shares of the cardiovascular self-measurement device company have managed to see highs of $0.4844 within the last 45 days and after the company's recent announcement, it would appear that trading activity continues to remain higher than it was during the last week of December."
https://marketersmedia.com/2-healthcare-testing-diagnostic-stocks-taking-center-stage-ahead-of-jp-morgan-conference/285274
"Lexington Biosciences ("LXGTF") has been working on its novel HeartSentry device. The device focuses on endothelial cells that line all the arteries in the body. The HeartSentry is being developed to measure the function of the endothelium to gain early detection for things like heart attack, stroke, and even a way to possibly prevent atherosclerosis. The device targets the growth that the "self-measurement medical device sector" is beginning to see. In fact, that quote helps promote the fact that this "self-directed" diagnostic niche has become a more prevalent niche for medical technology and for the tech industry in general.
Nearly 1 in 3 deaths in the USA are caused by heart disease and stroke.
Of the approximately 1.5 million people suffering heart attacks annually in the U.S., more than 250,000 will die within one hour of their incident. This is what the company's device looks to address."
https://finance.yahoo.com/news/technology-stocks-see-increase-momentum-155500048.html
"Lexington Biosciences, Inc. ("LXGTF") has begun to progress toward upcoming pilot clinical studies for its HeartSentry device. The studies will be designed to gather the baseline data to support FDA clearance. Furthermore, in response to recent announcements that the company would be engaging Nagicant Consulting to help develop coverage policies to support HeartSentry's commercial rollout, Lexington's President Eric Willis said, "As recently announced, we are moving ahead quickly towards the commencement of our HeartSentry pilot clinical research study designed to build the foundational dataset ultimately aimed at supporting FDA clearance. As we plan for market entry, we know that a key element to commercial success will come from fielding a product that meets the threshold for medical insurance coverage."
https://finance.yahoo.com/news/2-medical-technology-stocks-investors-190200410.html
no, not mgmt
power hour 'n stuff
heating up...Knoll Capital Management takes SNGX position....
"Having someone like Fred Knoll take a position in Soligenix is very meaningful given he was one of the early investors in Medivation when the company was a microcap company, just like Soligenix is today. On August 22nd last year, Pfizer Inc. (NYSE:PFE) and Medivation, Inc. (formerly NASDAQ:MDVN) announced that they had entered into a definitive merger agreement under which Pfizer would acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion. Yes, you read that correctly, they were acquired for $14B. So why is Fred Knoll buying Soligenix at $2.00 and the share price of Soligenix as of the date of this article is $1.93? My answer, people are not connecting the dots and my hope is that this article helps get those dots connected.
A well respected investment group like Knoll Capital Management, LP does not put its money into ideas it thinks will fail and I have found that following funds like Knoll and others in the biotech space, can prove to be a profitable endeavor in the long run. Some other companies the fund holds can be found here: https://whalewisdom.com/filer/knoll-capital-management-lp. An article from Forbes discussing Knoll Capital Management, LP and its investment in Medivation can be found here: https://www.forbes.com/sites/nathanvardi/2016/05/12/the-man-who-made-a-personal-fortune-off-of-cancer-drug-maker-medivation/#6741eb122abb
In case you missed what else Soligenix has accomplished recently:
In November 2017, Soligenix announced that it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority’s (NJEDA) New Jersey Technology Business Tax Certificate Transfer program. As a result, the Company anticipates being able to transfer this credit and receive approximately $417,000 in net proceeds by year end.
In September 2017, the National Institutes of Health (NIH) awarded the company approximately $700,000 over five years for the development of a thermostabilized Ebola vaccine.
In September 2017, the National Institute of Dental and Craniofacial Research (NIDCR), part of the NIH, awarded the company a Small Business Innovation Research (SBIR) grant of approximately $1.5 million over two years to support the conduct of its pivotal, Phase III, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide) as a treatment for severe oral mucositis in patients with head and neck cancer receiving chemoradiation therapy.
In September 2017, the National Cancer Institute (NCI), part of the NIH, awarded Soligenix a SBIR grant of approximately $1.5 million over two years to support the conduct of its pivotal, Phase III, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin) as a treatment for cutaneous T-cell lymphoma (CTCL).
In August 2017, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, exercised a $2.5 million option to fund GMP (good manufacturing practice) compliant RiVax® bulk drug substance and finished drug product manufacturing, to advance the development of a thermostable ricin toxin vaccine.
Soligenix’s CEO Chris Schaber recently presented at the Biotech & Money Investival Showcase Presentation on November 14, 2017, you can view that presentation by clinking here or visiting:
yes, good things are nice